The Experts below are selected from a list of 4167 Experts worldwide ranked by ideXlab platform
R P Garay - One of the best experts on this subject based on the ideXlab platform.
-
enhancement by reproterol of the ability of Disodium Cromoglycate to stabilize rat mastocytes
Pulmonary Pharmacology & Therapeutics, 1999Co-Authors: N Eleno, E Gajate, J Macias, R P GarayAbstract:The beta2-adrenoceptor agonist reproterol and Disodium Cromoglycate (DSCG) are used in fixed combination for the treatment of asthma, because they act on bronchial smooth muscle and inflammatory cells, respectively. Here, we investigated if reproterol can also act in rat mast cells in vitro to facilitate the inhibitory action of Disodium Cromoglycate (DSCG) on histamine secretion induced by compound 48/80. Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. 36.7+/-6.2% at 1 microM of each compound, n=10 and n=8 respectively). Mast cell stabilization by DSCG (1-100 microM) was strongly and significantly enhanced in the presence of a fixed saturating concentration of reproterol (100 microM). Conversely, the combination of DSCG (1-100 microM) with the beta2-agonist used as reference compound, salbutamol (100 microM) did not inhibit histamine release more than DSCG alone. In combination with a saturating concentration of DSCG (100 microM), reproterol inhibited histamine release more than reproterol alone. The potent adenylate cyclase stimulator forskolin (50 microM) was able to inhibit histamine release to a similar extent as DSCG and significantly (P<0.05) enhanced the inhibition of histamine release by DSCG. Finally, the phosphodiesterase inhibitor theophylline (100 microM) was equipotent to reproterol and DSCG in stabilizing rat mast cells. In conclusion, reproterol enhances the ability of Disodium Cromoglycate to stabilize rat mast cells. This effect is not shared by salbutamol and can be, at least in part, independent of beta2-adrenoceptor stimulation.
K Ueda - One of the best experts on this subject based on the ideXlab platform.
-
Disodium Cromoglycate use in children and adolescents with asthma: correlation between plasma concentrations and protective effects for various inhalation methods.
Annals of allergy asthma & immunology : official publication of the American College of Allergy Asthma & Immunology, 1999Co-Authors: Yasuhiro Kato, K Muraki, M Fujitaka, N Sakura, K UedaAbstract:Few studies have addressed the association between the plasma concentration of Disodium Cromoglycate and its protective effects on patients with bronchial asthma. We measured plasma concentrations of Disodium Cromoglycate for various asthmatic treatments in children and adolescents and estimated plasma concentrations and protective effects. Disodium Cromoglycate as a 2-mg aerosol (n = 12), 4-mg aerosol (n = 5), or 20-mg nebulizer solution (n = 13) was inhaled by patients in remission. The plasma concentrations of Disodium Cromoglycate after 5 minutes of inhalation were 3.04 +/- 2.72 ng/mL in the 2-mg aerosol group, 2.95 +/- 0.86 ng/mL in the 4-mg aerosol group, and 7.72 +/- 4.65 ng/mL in the nebulizer solution group. Subjects who used the nebulizer exhibited markedly higher plasma concentrations of Disodium Cromoglycate. There was a significant correlation between the concentration of Disodium Cromoglycate at 5 minutes and the protective effect determined by a ratio of the difference in the asthma score between baseline and treatment periods to the baseline asthma score. When the plasma concentration of Disodium Cromoglycate is low, administration of larger aerosol dose or nebulization might be necessary.
-
Disodium Cromoglycate use in children and adolescents with asthma: correlation between plasma concentrations and protective effects for various inhalation methods
Annals of Allergy Asthma & Immunology, 1999Co-Authors: Yasuhiro Kato, K Muraki, M Fujitaka, N Sakura, K UedaAbstract:Background Few studies have addressed the association between the plasma concentration of Disodium Cromoglycate and its protective effects on patients with bronchial asthma. Objective We measured plasma concentrations of Disodium Cromoglycate for various asthmatic treatments in children and adolescents and estimated plasma concentrations and protective effects. Method Disodium Cromoglycate as a 2-mg aerosol (n = 12), 4-mg aerosol (n = 5), or 20-mg nebulizer solution (n = 13) was inhaled by patients in remission. Results The plasma concentrations of Disodium Cromoglycate after 5 minutes of inhalation were 3.04 ± 2.72 ng/mL in the 2-mg aerosol group, 2.95 ± 0.86 ng/mL in the 4-mg aerosol group, and 7.72 ± 4.65 ng/mL in the nebulizer solution group. Subjects who used the nebulizer exhibited markedly higher plasma concentrations of Disodium Cromoglycate. There was a significant correlation between the concentration of Disodium Cromoglycate at 5 minutes and the protective effect determined by a ratio of the difference in the asthma score between baseline and treatment periods to the baseline asthma score. Conclusion When the plasma concentration of Disodium Cromoglycate is low, administration of larger aerosol dose or nebulization might be necessary.
D.p. Evans - One of the best experts on this subject based on the ideXlab platform.
-
The mechansim of tachyphylaxis to ICI 74,917 and Disodium Cromoglycate.
International Archives of Allergy and Immunology, 2009Co-Authors: P.w. Marshall, D.s. Thomson, D.p. EvansAbstract:Pre-incubation in vitro of sensitised peritoneal mast cells for 10 min with either ICI 74,917 (10––5 M) or Disodium Cromoglycate (10––3 M) abolished the ability of either drug to inhibit histamine release when subsequently presented to the cells at the same time as antigen. In the case of Disodium Cromoglycate, tachyphylaxis was abolished by washing the cells after pre-incubation with the drug. The failure to abolish tachyphylaxis to ICI 74,917 was due to the high pre-incubation concentration employed, as at lower concentrations (10––8 M) tachyphylaxis to ICI 74,917 was readily abolished by washing. Tachyphylaxis to these anti-allergic agents may be related to a physical blocking of drug receptor sites on or in mast cells.
Yasuhiro Kato - One of the best experts on this subject based on the ideXlab platform.
-
Disodium Cromoglycate in children and adolescents with asthma: Correlation between plasma concentrations and protective effects for various inhalation methods
Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology, 1999Co-Authors: Yasuhiro KatoAbstract:We measured plasma concentrations of Disodium Cromoglycate for various asthmatic treatments in children and adolescents and estimated plasma concentrations and protective effects. Disodium Cromoglycate as a 2mg aerosol (n=13), 4mg aerosol (n=5), or 20mg nebuliser solution (n=13) was inhaled by patients when they had no asthmatic attacks. The plasma concentrations of Disodium Cromoglycate after 5min of inhalation were 3.04±2.72 ng/mL in the 2mg aerosol group, 2.95±0.86ng/mL in the 4mg aerosol group, and 7.72±4.65ng/mL in the nebuliser solution group. Subjects who used the nebuliser exhibited markedly higher plasma concentrations of Disodium Cromoglycate. There was a significant correlation between the concentration of Disodium Cromoglycate at 5min and the protective effect determined by a ratio of the difference in the asthma score between baseline and treatment periods to the baseline asthma score. When the plasma concentration of Disodium Cromoglycate is low, administration of larger aerosol dose or nebulisation might be necessary.
-
Disodium Cromoglycate use in children and adolescents with asthma: correlation between plasma concentrations and protective effects for various inhalation methods.
Annals of allergy asthma & immunology : official publication of the American College of Allergy Asthma & Immunology, 1999Co-Authors: Yasuhiro Kato, K Muraki, M Fujitaka, N Sakura, K UedaAbstract:Few studies have addressed the association between the plasma concentration of Disodium Cromoglycate and its protective effects on patients with bronchial asthma. We measured plasma concentrations of Disodium Cromoglycate for various asthmatic treatments in children and adolescents and estimated plasma concentrations and protective effects. Disodium Cromoglycate as a 2-mg aerosol (n = 12), 4-mg aerosol (n = 5), or 20-mg nebulizer solution (n = 13) was inhaled by patients in remission. The plasma concentrations of Disodium Cromoglycate after 5 minutes of inhalation were 3.04 +/- 2.72 ng/mL in the 2-mg aerosol group, 2.95 +/- 0.86 ng/mL in the 4-mg aerosol group, and 7.72 +/- 4.65 ng/mL in the nebulizer solution group. Subjects who used the nebulizer exhibited markedly higher plasma concentrations of Disodium Cromoglycate. There was a significant correlation between the concentration of Disodium Cromoglycate at 5 minutes and the protective effect determined by a ratio of the difference in the asthma score between baseline and treatment periods to the baseline asthma score. When the plasma concentration of Disodium Cromoglycate is low, administration of larger aerosol dose or nebulization might be necessary.
-
Disodium Cromoglycate use in children and adolescents with asthma: correlation between plasma concentrations and protective effects for various inhalation methods
Annals of Allergy Asthma & Immunology, 1999Co-Authors: Yasuhiro Kato, K Muraki, M Fujitaka, N Sakura, K UedaAbstract:Background Few studies have addressed the association between the plasma concentration of Disodium Cromoglycate and its protective effects on patients with bronchial asthma. Objective We measured plasma concentrations of Disodium Cromoglycate for various asthmatic treatments in children and adolescents and estimated plasma concentrations and protective effects. Method Disodium Cromoglycate as a 2-mg aerosol (n = 12), 4-mg aerosol (n = 5), or 20-mg nebulizer solution (n = 13) was inhaled by patients in remission. Results The plasma concentrations of Disodium Cromoglycate after 5 minutes of inhalation were 3.04 ± 2.72 ng/mL in the 2-mg aerosol group, 2.95 ± 0.86 ng/mL in the 4-mg aerosol group, and 7.72 ± 4.65 ng/mL in the nebulizer solution group. Subjects who used the nebulizer exhibited markedly higher plasma concentrations of Disodium Cromoglycate. There was a significant correlation between the concentration of Disodium Cromoglycate at 5 minutes and the protective effect determined by a ratio of the difference in the asthma score between baseline and treatment periods to the baseline asthma score. Conclusion When the plasma concentration of Disodium Cromoglycate is low, administration of larger aerosol dose or nebulization might be necessary.
N Eleno - One of the best experts on this subject based on the ideXlab platform.
-
enhancement by reproterol of the ability of Disodium Cromoglycate to stabilize rat mastocytes
Pulmonary Pharmacology & Therapeutics, 1999Co-Authors: N Eleno, E Gajate, J Macias, R P GarayAbstract:The beta2-adrenoceptor agonist reproterol and Disodium Cromoglycate (DSCG) are used in fixed combination for the treatment of asthma, because they act on bronchial smooth muscle and inflammatory cells, respectively. Here, we investigated if reproterol can also act in rat mast cells in vitro to facilitate the inhibitory action of Disodium Cromoglycate (DSCG) on histamine secretion induced by compound 48/80. Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. 36.7+/-6.2% at 1 microM of each compound, n=10 and n=8 respectively). Mast cell stabilization by DSCG (1-100 microM) was strongly and significantly enhanced in the presence of a fixed saturating concentration of reproterol (100 microM). Conversely, the combination of DSCG (1-100 microM) with the beta2-agonist used as reference compound, salbutamol (100 microM) did not inhibit histamine release more than DSCG alone. In combination with a saturating concentration of DSCG (100 microM), reproterol inhibited histamine release more than reproterol alone. The potent adenylate cyclase stimulator forskolin (50 microM) was able to inhibit histamine release to a similar extent as DSCG and significantly (P<0.05) enhanced the inhibition of histamine release by DSCG. Finally, the phosphodiesterase inhibitor theophylline (100 microM) was equipotent to reproterol and DSCG in stabilizing rat mast cells. In conclusion, reproterol enhances the ability of Disodium Cromoglycate to stabilize rat mast cells. This effect is not shared by salbutamol and can be, at least in part, independent of beta2-adrenoceptor stimulation.
